Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protégé Study: Teplizumab in Recent-Onset Type 1 Diabetes
NCT00385697Phase 3Completed
- Sponsor
- MacroGenics
- Start
- Oct 2006
- Primary completion
- Jun 2010
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of teplizumab in type 1 diabetes mellitus (T1D), sponsored by MacroGenics. Started Oct 2006; status: completed.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00385697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00385697.